Article
How can we reduce costs of solid-phase multiplex-bead assays used to determine anti-HLA antibodies?
HLA - 1 Sept 2016
Kamburova E G, Wisse B W, Joosten I, Allebes W A, van der Meer A, Hilbrands L B, Baas M C, Spierings E, Hack C E, van Reekum F E, van Zuilen A D, Verhaar M, Bots M L, Drop A C A D, Plaisier L, Seelen M A J, Sanders J S F, Hepkema B G, Lambeck A J, Bungener L B, Roozendaal C, Tilanus M G J, Vanderlocht J, Voorter C E, Wieten L, van Duijnhoven E M, Gelens M, Christiaans M H L, van Ittersum F J, Nurmohamed A, Lardy N M, Swelsen W, van der Pant K A, van der Weerd N C, Ten Berge I J M, Bemelman F J, Hoitsma A, van der Boog P J M, de Fijter J W, Betjes M G H, Heidt S, Roelen D L, Claas F H, Otten H G
Abstract excerpt
Solid-phase multiplex-bead assays are widely used in transplantation to detect anti-human leukocyte antigen (HLA) antibodies. These assays enable high resolution detection of low levels of HLA antibodies. However, multiplex-bead assays are costly and yield variable measurements that limit the comparison of results between laboratories. In the context of a Dutch national Consortium study we aimed to determine the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
